Resultados: 3

    Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline

    BMJ; e080257 (), 2024
    What is the impact of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on survival and on cardiovascular and kidneyoutcomes for adults living with chronic kidney disease (CKD)? Few therapies slow kidney disease progression and improve long term prognosis for adults living with CKD. SGLT-2 inhibitors ha...

    CARI Guidelines: urate-lowering treatment in early CKD

    The scope of the guideline is urate-lowering therapy in patients with chronic kidney disease (not on dialysis) without symptomatic hyperuricemia (such as gout and/or uric acid stone formation). The guideline does not make recommendations about the management of uric-acid kidney stones or gout in people w...

    Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

    Kidney int; 99 (3), 2021
    The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease for patients not receiving dialysis represents an update to the KDIGO 2012 guideline on this topic. Development of this guideline update followed a rigorou...